InnoCare Pharma

InnoCare Pharma is a commercial-stage biopharmaceutical company focused on discovering, developing, and commercializing first-in-class and best-in-class therapies for cancer and autoimmune diseases. The company's lead product, orelabrutinib (ICP-022), is a highly selective Bruton's tyrosine kinase (BTK) inhibitor approved in China for multiple B-cell malignancies and is being evaluated for autoimmune indications like multiple sclerosis. InnoCare maintains a robust pipeline of small molecules and biologics targeting key pathways such as FGFR, TRK, and SHP2, with several programs in late-stage clinical development. Headquartered in Beijing with R&D centers in the US and China, the company leverages its proprietary drug discovery platform to address significant unmet medical needs globally.